Loading...
Home2019-07-30T19:34:57+00:00

Unprecedented Insights

ImaginAb is an emerging immune-oncology imaging company developing a pipeline of novel products that give physicians unprecedented insights into the patient’s health—enabling better patient selection and treatment monitoring for immuno-oncology therapies and other drugs.

Harnessing the specificity of monoclonal antibodies, ImaginAb designs and engineers small, highly targeted proteins known as minibodies that image important molecular targets using standard Positron Emission Tomography (PET).

Our imaging tools help physicians answer important clinical questions, improving the path of care and ultimately helping patients live longer, healthier lives.

We image critical targets in immuno-oncology to help patients and their doctors make better-informed treatment decisions.

100%

ACCURACY

100%

INNOVATION

100%

CLARITY

100%

BETTER DATA

Read latest publications

ImaginAb to Present at Upcoming Investor and Scientific Conferences in September & October 2019

ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces that it is scheduled to attend and/or present at the following investor and scientific conferences in September and October 2019: Word Molecular Imaging Congress, ESMO Congress, Cavendish Global Conference: The 2019 Phoenix BioHealth Impact Forum, 2nd Annual Advances in Immuno-Oncology USA Congress, and Optimum 11th Annual Healthcare Investor Conference.